Plain-English translation of NCT06494501 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if aggressively lowering cholesterol levels in younger adults can prevent heart disease before symptoms ever appear. The study focuses on people who already show early, silent signs of plaque building up in their arteries—a condition many people don't even know they have. Researchers hope that this medication, combined with diet and lifestyle changes, can stop or slow that buildup and keep hearts healthier long-term.
Heart disease is the leading cause of death worldwide, but most prevention happens only after someone has a heart attack or stroke. This trial exists because new research suggests that lowering cholesterol much more aggressively in younger, apparently healthy people—before any symptoms appear—could prevent disease from developing in the first place. There is no large clinical trial yet proving this approach works, so this study aims to provide that evidence.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive the new medication () plus intensive diet and lifestyle counseling, or to receive standard cholesterol treatment according to current medical guidelines. You will visit the clinic every 2 months initially to check your cholesterol levels and blood pressure, with the goal of reaching very low cholesterol levels and controlled blood pressure. The study lasts 5 years, during which you'll receive the medication by injection and have regular follow-up visits and imaging tests to monitor whether the plaque in your arteries is slowing down or stopping.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States